ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

CD8+ TAb-supp Cells Are Key Inhibitors of Humoral Alloimmunity by Inhibiting CD4+TFH Cells and Killing Germinal Center B Cells.

J. Zimmerer, C. Avila, S. Elzein, B. Ringwald, R. Warren, G. Bumgardner.

Surgery, The Ohio State University Wexner Medical Center, Columbus, OH

Meeting: 2017 American Transplant Congress

Abstract number: C300

Keywords: B cells, Interferon (IFN), T cells, T helper cells

Session Information

Session Name: Poster Session C: Tolerance/Immune Regulation

Session Type: Poster Session

Date: Monday, May 1, 2017

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall D1

Alloantibodies (alloAb) play a critical role in acute and chronic rejection after transplantation (Tx). It is well known that CD4+ T cells and B cells collaborate for antibody (Ab) production. Our group has reported, in a well-characterized murine hepatocyte (Hc) Tx model, that alloAb production requires CD4+ T cells, type I NKT cells, lymph nodes, and CD40/CD40L interactions. In contrast, we have recently reported a novel Ab-suppressing CD8+ T cell subset, or CD8+ TAb-supp cells, that inhibits alloAb production postTx, in part by killing alloAb producing IgG1+ B cells. In addition, we have also reported that CD8+ TAb-supp cells inhibit the number of splenic IL-4+CD4+ T cells detected in vivo postTx. In order to further investigate the cellular targets and mechanisms of CD8+ TAb-supp cell effector function, we utilized OVA antigen [from C57BL/6 mOVA transgenic Hc lysate (H-2b)] to stimulate anti-OVA antibody. Similar to CD8+ TAb-supp cell postTx, OT-I Tg CD8+ T cells (specific to OVA antigen) negatively regulate the quantity of anti-OVA Ab produced in mOVA treated CD8 KO recipients (285±21 ng/mL with adoptive transfer of OT-I cells vs 519±97 ng/mL without CD8+ T cells; p=0.01) and kill IgG1+ B cells (22±3% in vivo B cell apoptosis vs 4±0.9% for naïve OT-I Tg CD8+ T cells; p<0.001). We hypothesized that CD8+ TAb-supp cells inhibit Ab titer by downregulating cells in the germinal center (GC) including CD4+ TFH cells (CXCR5+ICOS+PD-1+CD4+ T cells) and GC B cells (B220+CXCR5+CXCR4+GL-7+ B cells). Following adoptive transfer of OT-I CD8+ T cells into CD8 KO mOVA treated recipients, the number of IL-21+CD4+ TFH cells (2.3±0.1 x104 cells/million CD4+ T cells) was significantly decreased compared to untreated CD8 KO mOVA recipients (4.2±0.2 x104 cells/million CD4+ T cells; p=0.01). In addition, the number of GC B cells were significantly reduced by AT of OT-I Tg CD8+ T cells into CD8 KO mOVA stimulated recipients (5±0.6 x103 cells/million B cells) compared to mOVA treated CD8 KO mice (13.1±0.9 x103 cells/million B cells; p=0.02). This data suggests that CD8+ TAb-supp cells inhibit Ab production through at least two mechanisms including the inhibition of maturation and/or effector function of IL-21+CD4+ TFH cells and killing GC B cells.

CITATION INFORMATION: Zimmerer J, Avila C, Elzein S, Ringwald B, Warren R, Bumgardner G. CD8+ TAb-supp Cells Are Key Inhibitors of Humoral Alloimmunity by Inhibiting CD4+TFH Cells and Killing Germinal Center B Cells. Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Zimmerer J, Avila C, Elzein S, Ringwald B, Warren R, Bumgardner G. CD8+ TAb-supp Cells Are Key Inhibitors of Humoral Alloimmunity by Inhibiting CD4+TFH Cells and Killing Germinal Center B Cells. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/cd8-tab-supp-cells-are-key-inhibitors-of-humoral-alloimmunity-by-inhibiting-cd4tfh-cells-and-killing-germinal-center-b-cells/. Accessed May 11, 2025.

« Back to 2017 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences